Journal of Inflammation Research (May 2024)

Effects of Repeated Doses of the Vero Cell Vaccine (SARS-Cov-2 Inactivated Vaccine) on Renal Functions in Balb/C Albino Mice

  • Köse Ş,
  • Yılmaz C,
  • Kıratlı K,
  • Çelebi Ç,
  • Akan P,
  • Kumas Kulualp M,
  • Duman S,
  • Yılmaz O

Journal volume & issue
Vol. Volume 17
pp. 2851 – 2860

Abstract

Read online

Şükran Köse,1 Canberk Yılmaz,2 Kazım Kıratlı,3 Çağlar Çelebi,4 Pınar Akan,5 Meltem Kumas Kulualp,6 Soner Duman,7 Osman Yılmaz8 1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey; 2Department of Pediatrics, Faculty of Medicine, Health Sciences University, Izmir, Turkey; 3Department of Infectious Diseases and Clinical Microbiology, Mogadishu Somalia Turkey Recep Tayyip Erdoğan Training and Research Hospital, Mogadishu, Somalia; 4Department of Medical Biology, Institute of Health Sciences, Ege University, Izmir, Turkey; 5Department of Medical Biochemistry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey; 6Department of Histology and Embryology, Faculty of Veterinary Medicine, Dokuz Eylul University, Izmir, Turkey; 7Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey; 8Department of Laboratory Animal Science, Institute of Health Sciences, Dokuz Eylul University, Izmir, TurkeyCorrespondence: Kazım Kıratlı, Mogadishu Somalia Turkey Recep Tayyip Erdoğan Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Mogadishu, Somalia, Tel +252 611 522 947 ; +90 537 252 84 86, Email [email protected]: Many of the vaccines developed for COVID-19 have been approved for clinical emergency use before their safety and preclinical studies have been completed. The main aim of this study was to investigate the effects of an inactivated SARS-CoV-2 virus vaccine (Vero cells) on renal function in Balb/C Albino mice.Methods: 21 healthy, 6– 8 week old BALB/c male mice were divided into three equal groups, and 0.10 mL of intramuscular saline equal to the vaccine dose volume was administered to the first group. To the second group, a single dose of 0.10 mL 120 U of Vero cell inactive SARS COV-2 vaccine was administered intramuscularly. Group 3 received two consecutive doses of 0.10 mL 120 U intramuscular Vero cell inactive SARS COV-2 vaccine, 14 days apart. After administration, the clinical status, fecal and urine status, nutritional status and kidney histopathology of the mice were evaluated.Results: It was determined that no acute toxic symptoms were observed in the mice administered the vaccine, they were in good condition, and there was no significant stimulatory reaction related to the vaccine in the tissues of the injected local area. There was no difference in feed consumption, water consumption, and body weight gains between the control group, the groups that received a single dose of vaccine, and the groups that received two doses of vaccine (p> 0.05). No difference was found between the groups when urine and feces amounts were compared (p> 0.05). No difference was found between the groups when urinary urea, creatinine, and serum BUN, creatinine levels were compared (p> 0.05). No difference was found in the histopathological evaluation of the kidneys between the groups (p> 0.05).Conclusion: In conclusion, single or repeated injections of the SARS-CoV-2 vaccine (Vero cells) into mice were found to have no adverse effects on the animals’ overall clinical health, performance abilities and kidneys.Keywords: COVID-19, vaccine, SARS CoV-2, adverse effect, kidney

Keywords